South San Francisco, Calif. — October 3, 2025 — Leads & Copy — ALX Oncology Holdings Inc. (Nasdaq: ALXO) will share data demonstrating CD47 overexpression as a key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland, the company announced today.
The Phase 2 ASPEN-06 (NCT05002127) trial evaluated evorpacept, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.
The poster presentation will include the title: CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial. First author: Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of GI Oncology Program, University of California, Los Angeles. Abstract: 496. Date and Time: Saturday, November 8, 2025, 10:00 a.m. – 6:35 p.m. ET. Location: Poster Hall (Exhibit Halls AB)
ASPEN-06 is a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, evaluating evorpacept in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with metastatic second- or third-line HER2 overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
Source: ALX Oncology
